International Journal of Clinical Oncology

, Volume 13, Issue 2, pp 102–111 | Cite as

The role of cancer registries in cancer control

  • Donald Maxwell ParkinEmail author
Review Article


Cancer control aims to reduce the incidence, morbidity, and mortality of cancer and to improve the quality of life of cancer patients through the systematic implementation of evidence-based interventions in prevention, early diagnosis, treatment, and palliative care. In the context of a national cancer control program (NCCP), a cancer surveillance program (CSP), built around a population-based cancer registry, is an essential element. Data on the size and evolution of the cancer burden in the population are essential to evaluation of the current situation, to setting objectives for cancer control, and defining priorities. Cancer data are essential in monitoring the progress of the implementation of an NCCP, as well as providing an evaluation of the many individual cancer control activities. In the context of an NCCP, the CSP should provide a focus of epidemiological expertise, not only for providing statistical data on incidence, mortality, stage distribution, treatment patterns, and survival but also for conducting studies into the important causes of cancer in the local situation, and for providing information about the prevalence of exposure to these factors in the population. Cancer surveillance via the population-based registry therefore plays a crucial role in formulating cancer control plans, as well as in monitoring their success.

Key words

Cancer registration Cancer control Surveillance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organisation (2002) National cancer control programmes. Policies and managerial guidelines, 2nd edn., WHO, GenevaGoogle Scholar
  2. 2.
    Muir CS, Demaret E, Boyle P (1985) The cancer registry in cancer control: an overview. In: Parkin DM, Wagner G, Muir CS (eds) The role of the registry in cancer control. IARC Scientific Publications no. 66., IARC, Lyon, pp 13–26Google Scholar
  3. 3.
    Armstrong BK (1992). The role of the registry in cancer control. Cancer Causes Control 3:569–579PubMedCrossRefGoogle Scholar
  4. 4.
    World Health Organisation (1973) Environmental and health surveillance in occupational medicine. Technical report series no. 535. WHO, Geneva, p 7Google Scholar
  5. 5.
    Hiatt RA, Rimer BK (1999) A new strategy for cancer control research. Cancer Epidemiol Biomarkers Prev 8:957–964PubMedGoogle Scholar
  6. 6.
    World Health Organisation (2003) World health report 2003 “Shaping the future”. WHO, Geneva (also available at: Scholar
  7. 7.
    Hakama M, Hakulinen T, Teppo L, et al. (1975) Incidence, mortality or prevalence as indicators of the cancer problem. Cancer 36:2227–2231PubMedGoogle Scholar
  8. 8.
    Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97:72–81PubMedCrossRefGoogle Scholar
  9. 9.
    Adami HO, Gunnarson T, Spaŕen P, et al. (1989) The prevalence of cancer in Sweden. Acta Oncol 4:463–470CrossRefGoogle Scholar
  10. 10.
    Capocaccia R, Colonna M, Corazziari I, et al. (2002) Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 13:831–839PubMedCrossRefGoogle Scholar
  11. 11.
    Jensen OM, Carstensen B, Glattre E, et al. (1988) Atlas of cancer incidence in the Nordic countries. Nordic Cancer Union, HelsinkiGoogle Scholar
  12. 12.
    Miller BA, Kolonel LN, Bernstein L, et al. (eds) (1996) Racial/Ethnic patterns of cancer in the United States 1988–1992. NIH Publication no. 96-4104. National Cancer Institute, Bethesda, MDGoogle Scholar
  13. 13.
    Singh GK, Miller BA, Hankey BF, et al. (2003) Area socioeconomic variations in US cancer incidence, mortality, stage, treatment, and survival, 1975–1999. NCI Cancer Surveillance Monograph Series, number 4. NIH Publication no. 03-5417. National Cancer Institute, Bethesda, MDGoogle Scholar
  14. 14.
    Roche LM, Skinner R, Weinstein RB (2002) Use of a geographic information system to identify and characterize areas with high proportions of distant stage breast cancer. J Public Health Manag Pract 8:26–32PubMedGoogle Scholar
  15. 15.
    Adams J, White M, Forman D (2004) Are there socioeconomic gradients in stage and grade of breast cancer at diagnosis? Cross sectional analysis of UK cancer registry data. BMJ 329:142 [Epub]PubMedCrossRefGoogle Scholar
  16. 16.
    Greenwald P, Cullen JW, McKenna JW (1987) Cancer prevention and control, from research through applications. J Natl Cancer Inst 79:389–400PubMedGoogle Scholar
  17. 17.
    Scottish Executive (2003) NHS National targets, related to NHS national priorities.
  18. 18.
    World Health Organisation, Regional Office for Europe (1985) Targets for health for all. European Health for all Series, no. 1. WHO, CopenhagenGoogle Scholar
  19. 19.
    European Union (European Parliament and Council Decision) Europe Against Cancer, action plan (1996–2002). Official Journal L 95,16.04.1996 []
  20. 20.
    Bray F, Moller B (2006) Predicting the future burden of cancer. Nat Rev Cancer 6:63–74PubMedCrossRefGoogle Scholar
  21. 21.
    Møller B, Fekjær H, Hakulinen T, et al. (2002) Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev 11(Suppl): S1–S96PubMedGoogle Scholar
  22. 22.
    Coory M, Armstrong BK (1998) Cancer Incidence projections for area and rural health services in New South Wales. NSW Cancer Council, SydneyGoogle Scholar
  23. 23.
    Stockton D (2004) Cancer in Scotland, Sustaining change. Cancer incidence projections for Scotland (2001–2020) An aid to planning cancer services. NHS Scotland, Edinburgh, Google Scholar
  24. 24.
    Boyle P, Zaridze DG (1983) Colorectal cancer as a disease of the environment. Ecol Dis 2:241–248PubMedGoogle Scholar
  25. 25.
    Cummings JH, Bingham SA (1998) Diet and the prevention of cancer. Br Med. J 317:1636–1640Google Scholar
  26. 26.
    Armstrong B, Doll R (1975) Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15:617–631PubMedCrossRefGoogle Scholar
  27. 27.
    McMichael AJ, McCall MG, Hartshorne JM, et al. (1980) Patterns of gastrointestinal cancer in European migrants to Australia; the role of dietary change. Int J Cancer 5:431–437CrossRefGoogle Scholar
  28. 28.
    Key TJ, Allen NE, Spencer EA, et al. (2002) The effect of diet on the risk of cancer. Lancet 360:861–868PubMedCrossRefGoogle Scholar
  29. 29.
    Yoshimi I, Ohshima A, Ajiki W, et al. (2003) A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA. Jpn J Clin Oncol 33:98–104PubMedCrossRefGoogle Scholar
  30. 30.
    Forman D (2004) Review article: oesophago-gastric adenocarcinoma — an epidemiological perspective. Aliment Pharmacol Ther 20(Suppl 5):55–60PubMedCrossRefGoogle Scholar
  31. 31.
    Chatterjee N, Hartge P, Cerhan JR, et al. (2004) Risk of non-Hodgkin’s lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev 13:1415–1421PubMedGoogle Scholar
  32. 32.
    Breslow NE (2005) Case control studies. In: Ahrens W, Pigeot I. (eds) Handbook of epidemiology. Springer, Berlin Heidelberg New York Tokyo, pp 287–319CrossRefGoogle Scholar
  33. 33.
    Kjaerheim K (1999) Occupational cancer research in the Nordic countries. Environ Health Perspect 107(Suppl 2):233–238PubMedCrossRefGoogle Scholar
  34. 34.
    Mbulaiteye SM, Katabira ET, Wabinga H, et al. (2006) Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 118:985–990PubMedCrossRefGoogle Scholar
  35. 35.
    Travis LB (2002) Therapy-associated solid tumors. Acta Oncol 41:323–333PubMedCrossRefGoogle Scholar
  36. 36.
    Hakulinen T, Pukkala E, Kenward M, et al. (1990) Changes in cancer incidence in North Karelia, an area with a comprehensive preventive cardiovascular programme. In: Hakama M, Beral V, Cullen V, Parkin DM (eds) Evaluating effectiveness of primary prevention of cancer. International Agency for Research on Cancer Scientific Publications, Lyon, pp 133–148Google Scholar
  37. 37.
    Jemal A, Cokkinides VE, Shafey O, Thun MJ (2003) Lung cancer trends in young adults: an early indicator of progress in tobacco control (United States). Cancer Causes Control 14:579–585PubMedCrossRefGoogle Scholar
  38. 38.
    Chang MH, Chen CJ, Lai MS, et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855–1859PubMedCrossRefGoogle Scholar
  39. 39.
    Weir HK, Thun M., Hankey BF, et al. (2003) Annual report to the nation on the status of cancer 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276–1299PubMedGoogle Scholar
  40. 40.
    Barnoya J, Glantz S (2004) Association of the California tobacco control program with declines in lung cancer incidence. Cancer Causes Control 15:689–695PubMedCrossRefGoogle Scholar
  41. 41.
    Sankila R, Démaret E, Hakama M, et al. (eds) (2001) Evaluation and monitoring of cancer screening programmes. European Commission, Brussels-LuxembourgGoogle Scholar
  42. 42.
    Fidler HK, Boyes DA, Worth AJ (1968) Cervical cancer detection in British Columbia. A progress report. J Obstet Gynaecol Br Commonw 75:392–404PubMedGoogle Scholar
  43. 43.
    Pettersson F, Näslund I, Malker B (1986) Evaluation of the effect of Papanicolaou screening in Sweden: record linkage between a control screening registry and the National Cancer Registry. In: Hakama M, Miller AB, Day NE (eds) Screening for cancer of the uterine cervix. IARC Scientific Publication no. 76. IARC, LyonGoogle Scholar
  44. 44.
    Oshima A, Hanai A, Fujimoto I (1979) Evaluation of a mass screening program for stomach cancer. NCI Monogr 53:181–186Google Scholar
  45. 45.
    Tsubono Y, Nishino Y, Tsuji I, et al. (2000) Screening for gastric cancer in Miyagi, Japan: evaluation with a population-based cancer registry. Asian Pac J Cancer Prev 1:57–60PubMedGoogle Scholar
  46. 46.
    Lee KJ, Inoue M, Otani T, et al. (2006) Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 118:2315–2321PubMedCrossRefGoogle Scholar
  47. 47.
    Hakama M, Pukkala E, Heikkila M, et al. (1997) Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ 314:864–867PubMedGoogle Scholar
  48. 48.
    Morrison AS (1985) Screening in chronic disease. Oxford University Press, New YorkGoogle Scholar
  49. 49.
    Gordon NP, Hiatt RA, Lampert DI (1993) Concordance of self-reported data and medical record audit for six cancer screening procedures. J Natl Cancer Inst 85:566–570PubMedCrossRefGoogle Scholar
  50. 50.
    Moss SM (1991) Case-control studies of screening. Int J Epidemiol 20:1–6PubMedCrossRefGoogle Scholar
  51. 51.
    Friedman DR, Dubin N (1991) Case-control evaluation of breast cancer screening efficacy. Am J Epidemiol 133:974–984PubMedGoogle Scholar
  52. 52.
    Weiss NS (1998) Analysis of case-control studies of the efficacy of screening for cancer: How should we deal with tests done in persons with symptoms? Am J Epidemiol 147:1099–1102PubMedGoogle Scholar
  53. 53.
    Morris JK (2002) Screening for neuroblastoma in children. J Med Screen. 9:56PubMedCrossRefGoogle Scholar
  54. 54.
    Day NE, Williams DR, Khaw KT (1989) Breast cancer screening programmes, the development of a monitoring and evaluation system. Br J Cancer 59:954–958PubMedGoogle Scholar
  55. 55.
    Schouten LJ, de-Rijke JM, Schlangen JT, et al. (1998) Evaluation of the effect of breast cancer screening by record linkage with the cancer registry, the Netherlands. J Med. Screen 5:37–41PubMedGoogle Scholar
  56. 56.
    McCann J, Stockton D, Day N (1998) Breast cancer in East Anglia, the impact of the breast screening programme on stage at diagnosis. J Med Screen 5:42–48PubMedGoogle Scholar
  57. 57.
    Hakama M, Magnus K, Pettersson F, et al. (1991) Effect of organized screening on the risk of cervical cancer in the Nordic countries. In: Miller A, Chamberlain J, Day N, et al. (eds) Cancer screening. Cambridge University Press, Cambridge, UK, pp 153–162Google Scholar
  58. 58.
    Walter SD, Day NE (1983) Estimation of the duration of a preclinical disease state using screening data. Am J. Epidemiol 118:865–886PubMedGoogle Scholar
  59. 59.
    Johannesson G, Geirsson G, Day NE (1978) The effect of mass screening in Iceland 1965–1974, on the incidence and mortality of cervical cancer. Int J Cancer 21:418–425PubMedCrossRefGoogle Scholar
  60. 60.
    Hisamichi S, Fukao A, Sugawara N, et al. (1991) Evaluation of mass screening programme for stomach cancer in Japan. In: Miller AB, et al. (eds) Cancer screening. Cambridge University Press, Cambridge, UKGoogle Scholar
  61. 61.
    Chu KC, Tarone RE, Chow WH, et al. (1994) Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst 86:997–1006PubMedCrossRefGoogle Scholar
  62. 62.
    Chu KC, Tarone RE, Kessler LG, et al. (1996) Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88:1571–1579PubMedCrossRefGoogle Scholar
  63. 63.
    Taplin SH, Mandelson MT, Anderman C, et al. (1997) Mammography diffusion and trends in late stage breast cancer, evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 6:625–631PubMedGoogle Scholar
  64. 64.
    Stockton D, Davies T, Day N, et al. (1997) Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia, earlier diagnosis or better treatment. Br Med J 314:472–475Google Scholar
  65. 65.
    Brenner H, Soderman B, Hakulinen T (2002) Use of period analysis for providing more up-to-date estimates of long-term survival rates, empirical evaluation among 370 000 cancer patients in Finland. Int J Epidemiol 31:456–462PubMedCrossRefGoogle Scholar
  66. 66.
    Trimble EL, Carter CL, Cain D, et al. (1994) Representation of older patients in cancer treatment trials. Cancer 74(7 Suppl):2208–2214PubMedCrossRefGoogle Scholar
  67. 67.
    Black RJ, Sankaranarayanan R, Parkin DM (1998) Interpretation of population-based cancer survival data. In: Sankaranarayanan R, Black RJ, Parkin DM (eds) Cancer survival in developing countries. IARC Scientific Publication, no. 145, IARC, Lyon, pp 13–17Google Scholar
  68. 68.
    Erridge SC, Møller H, Price A, Brewster D (2007) International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol 4:570–577PubMedCrossRefGoogle Scholar
  69. 69.
    Berrino F, De Angelis R, Sant M, et al. (2007) EUROCARE Working Group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol 8:773–783PubMedCrossRefGoogle Scholar
  70. 70.
    Young JL, Ries LG, Pollack ES (1984) Cancer patient survival among ethnic groups in the United States, 1973–79. J Natl Cancer Inst 73:341–352PubMedGoogle Scholar
  71. 71.
    Welch HG, Schwartz LM, Woloshin S (2000) Are increasing 5-year survival rates evidence of success against cancer? JAMA 283:2975–2978PubMedCrossRefGoogle Scholar
  72. 72.
    Peto R, Boreham J, Clarke M, et al. (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 355:1822–1823PubMedCrossRefGoogle Scholar
  73. 73.
    Peto R (2000) Author’s reply, Lancet 356:593CrossRefGoogle Scholar
  74. 74.
    Clauser SB (2004) Use of cancer performance measures in population health, a macro-level perspective. J Natl Cancer Inst Monographs 33:142–154PubMedCrossRefGoogle Scholar
  75. 75.
    Sankila R, Black R, Coebergh JWC, et al. (2003) Evaluation of clinical care by cancer registries. IARC Technical Report no. 37. IARC, LyonGoogle Scholar
  76. 76.
    Edwards BK, Brown ML, Wingo PA, et al. (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407–1427PubMedGoogle Scholar
  77. 77.
    Morris E, Forman D, Haward B (2007) The impact of the Calman-Hine report: analysis of breast and colorectal cancer surgical workloads and the degree of surgical site specialization in the Yorkshire region of the UK, 1990–2000. Eur J Cancer Care (Engl) 16:150–155CrossRefGoogle Scholar
  78. 78.
    Schrag D, Panageas KS, Riedel E, et al. (2002) Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg 236:583–592PubMedCrossRefGoogle Scholar
  79. 79.
    Hodgson DC, Zhang W, Zaslavsky AM, et al. (2003) Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst 95:708–716PubMedCrossRefGoogle Scholar
  80. 80.
    Parks RW, Bettschart V, Frame S, et al. (2004) Benefits of specialisation in the management of pancreatic cancer: results of a Scottish population-based study. Br J Cancer 91:459–465PubMedCrossRefGoogle Scholar
  81. 81.
    Jones AP, Haynes R, Sauerzapf V, et al. (2007) Travel times to health care and survival from cancers in Northern England. Eur J Cancer Sep 19; [Epub ahead of print]Google Scholar
  82. 82.
    Menck HR, Cunningham MP, Jessup JM, et al. (1987) The growth and maturation of the National Cancer Data Base. Cancer 80:2296–2304CrossRefGoogle Scholar
  83. 83.
    Warren JL, Klabunde CN, Schrag D, et al. (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3–IV-18Google Scholar
  84. 84.
    Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488–3494PubMedCrossRefGoogle Scholar
  85. 85.
    Surveillance, Epidemiology and End Results Program. National Cancer Institute.
  86. 86.
    Remontet L, Estève J, Bouvier AM, et al. (2003) Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 51:3–30PubMedGoogle Scholar
  87. 87.
    Kamo K, Kaneko S, Satoh K, et al. (2007) A mathematical estimation of true cancer incidence using data from population-based cancer registries. Jpn J Clin Oncol 37:150–155PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2008

Authors and Affiliations

  1. 1.Clinical Trials Service Unit and Epidemiological Studies UnitUniversity of OxfordOxfordUK

Personalised recommendations